Data as of Aug 29
| +0.05 / +0.68%|
The 3 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 10.00, with a high estimate of 10.25 and a low estimate of 9.06. The median estimate represents a +35.13% increase from the last price of 7.40.
The current consensus among 3 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.